Australia markets open in 3 hours 36 minutes

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7300+0.1200 (+7.45%)
At close: 04:00PM EDT
1.7300 0.00 (0.00%)
After hours: 04:18PM EDT

PMV Pharmaceuticals, Inc.

1 Research Way
Princeton, NJ 08540
United States
609 642 6670
https://www.pmvpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees63

Key executives

NameTitlePayExercisedYear born
Dr. David H. Mack Ph.D.Co-Founder, CEO, President & Director762.02kN/A1962
Dr. Arnold J. Levine Ph.D.Co-Founder, Director & Member of Scientific Advisory Board140kN/A1940
Dr. Thomas E. Shenk Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1947
Mr. Michael CarulliChief Financial OfficerN/AN/AN/A
Mr. Robert TicktinGeneral Counsel, Head of Operations & Company SecretaryN/AN/A1962
Mr. Tim SmithSenior VP & Head of Corporate Development and Investor RelationsN/AN/AN/A
Ms. Crystal ZuckermanVice President of Human ResourcesN/AN/AN/A
Dr. Binh Vu Ph.D.Senior VP of Drug Discovery & CMCN/AN/AN/A
Dr. Deepika Jalota Pharm.D.Chief Development Officer579.96k87.59k1977
Dr. Marc Fellous M.D.Senior VP and Head of Clinical Development & Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Corporate governance

PMV Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.